- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04905862
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy (COViNEPH-1)
February 3, 2022 updated by: Leszek Tylicki, Medical University of Gdansk
Multi Center Study to Assess the Humoral and Cellular Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
They have also high rates of comorbid conditions and have varying degrees of immunosuppression, which puts them at risk of developing very severe forms of COVID-19 disease with fatality rates varying from 16% to 32%.
In such circumstances vaccination is the only chance to improve their extremely poor prognosis.
There is very little published data on the response to vaccination in dialyzed patients and kidney transplant recipients so far.
No data are available on the efficacy of vaccines against COVID-19 in patients treated with peritoneal dialysis (PD).
Furthermore, given the fact that disturbances of acquired immunity in dialyzed patients are many and diverse it is uncertain whether vaccinating against SARS CoV-2 in these population will result in sufficient immune response and, by consequence, protection against infection.
Registration studies on the basis of which population vaccinations are actually conducted were performed only in the general population.
There were no dialyzed patients and kidney transplant recipients in the study groups, so these patients are vaccinated with doses and schedules for people without chronic kidney disease.
It is not known whether vaccination under such standard schedule produces a sufficient immune response in them and how long it lasts.
That's why the aim of this study is to evaluate the humoral and cellular immune response after mRNA vaccine against COVID-19 with which patients treated with renal replacement therapy are vaccinated in Poland.
It will be a prospective, observational controlled study conducted in patients treated with renal replacement therapy (hemodialyzed subjects, patients treated with peritoneal dialysis and kidney transplant recipients) vaccinated with mRNA vaccine against COVID-19 according to common rules and manufactures recommendations.The control group will be made up of sex and age matched people without chronic kidney disease.The first goal of the study is to analyze seroconversion rate and titer magnitude of neutralizing IgG and IgA antibodies directed against spike (s) SARS-CoV-2 antigen after the first and the second dose of mRNA vaccine as well as after 3, 6, 9, 12 months after vaccination.
The second goal is to evaluate the cellular immune response tested using the ELISPOT method at the same time points as above.The immune response will be compared to patients without chronic kidney disease as well as between hemodialysis, peritoneal dialysis patients and kidney transplant recipients.
Study Overview
Status
Recruiting
Detailed Description
- Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated, which in the first stage of the study will be frozen in nitrogen. To generate serum, blood samples were centrifuged at room temperature at 2500 RPM for 10 minutes, aliquoted, frozen in -70˚C, and stored until use.
- The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.
- The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.
- The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells.
- The grading scales for side effects (the same as in the pivotal trial) used in this study were derived from the FDA Center for Biologics Evaluation and Research (CBER) guidelines on toxicity grading scales for healthy adult volunteers enrolled in preventive vaccine clinical trials.
- All medical data of patients from all groups will be extracted from their medical records.
Study Type
Observational
Enrollment (Anticipated)
180
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Leszek Tylicki, MD PhD
- Phone Number: 0048583492830
- Email: leszek.tylicki@gumed.edu.pl
Study Locations
-
-
-
Gdańsk, Poland
- Recruiting
- 7th Naval Hospital in Gdansk
-
Contact:
- Ewelina Puchalska-Reglińska, MD
- Email: e.puchalska@7szmw.pl
-
Gdynia, Poland
- Recruiting
- NZOZ Diaverum Gdynia
-
Contact:
- Waldemar Ślizień, MD PhD
- Email: waldemar.slizien@diaverum.com
-
Gdynia, Poland
- Recruiting
- The University Centre of Maritime and Tropical Medicine in Gdynia
-
Contact:
- Marcin Renke, MD PhD
- Email: mrenke@gumed.edu.pl
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland, 80-211
- Recruiting
- Medical University of Gdansk
-
Contact:
- Leszek Tylicki, MD PhD
- Phone Number: +48583492830
- Email: leszek.tylicki@gumed.edu.pl
-
Sub-Investigator:
- Bogdan P Biedunkiewicz, MD PhD
-
Sub-Investigator:
- Alicja Dębska-Ślizień, MD PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients will be recruited in:
- Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk.
- NZOZ Diaverum Hemodialysis Unit in Gdynia.
- The University Centre of Maritime and Tropical Medicine in Gdynia
- 7th Naval Hospital in Gdansk
Description
Inclusion Criteria:
- patients on chronic dialysis (hemodialysis or peritoneal dialysis) for at least 1 months and had received vaccination with mRNA vaccine BNT162b2 (BionTech/Pfizer Comirnaty) with a 3-week interval between first and second doses.
Exclusion Criteria:
- (-)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hemodialyzed patients
Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
Patients treated with peritoneal dialysis
Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
Patients without chronic kidney disease
Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
Kidney transplant recipients
Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
|
The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials.
Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination.
Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral immune response
Time Frame: 12 months (7 time points)
|
Neutralizing IgG antibodies against the SARS-CoV (S1 and S2 subunits) (S)
|
12 months (7 time points)
|
Humoral immune response
Time Frame: 12 months (7 time points)
|
Neutralizing IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S)
|
12 months (7 time points)
|
The cellular immune response.
Time Frame: 12 months (7 time points)
|
Testing the amount of INF-γ and IL- 2 released from leukocyte cells in response to stimulation with S proteins
|
12 months (7 time points)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solicited and unsolicited local and systemic reactogenicity
Time Frame: Until 1 month after the second dose
|
Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events, i.e. those reported by the participants without prompts from the medical staff or observed by their physicians through 1 month after the second dose.
|
Until 1 month after the second dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2021
Primary Completion (Anticipated)
August 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
May 27, 2021
First Submitted That Met QC Criteria
May 27, 2021
First Posted (Actual)
May 28, 2021
Study Record Updates
Last Update Posted (Actual)
February 4, 2022
Last Update Submitted That Met QC Criteria
February 3, 2022
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency, Chronic
- COVID-19
- Kidney Failure, Chronic
- Renal Insufficiency
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Analgesics
- Antipyretics
Other Study ID Numbers
- COViNEPH-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Immune response
-
National Taiwan University HospitalCompletedDyspepsia | Gastric Ulcer | Duodenal UlcerTaiwan
-
Asociacion para el Estudio de las Enfermedades...RecruitingCovid19 | HIV-1-infection | Immune SuppressionSpain
-
Addario Lung Cancer Medical InstituteBiodesix, Inc.TerminatedNSCLC Stage IV | NSCLC, Stage IIICUnited States
-
Pontificia Universidad Catolica de ChileCompletedCovid19 | COVID-19 VaccinesChile
-
University Hospital, Clermont-FerrandRecruitingHospital Staff | Vaccined Againt COVID-19France
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Fundació Institut Germans Trias i Pujol; Institut Catala de Salut; IrsiCaixaRecruiting
-
Assistance Publique - Hôpitaux de ParisTerminatedCovid19 | Rheumatoid Arthritis | SpondyloarthritisFrance
-
CelgeneCompletedPancreatic CancerUnited States, Canada, Spain, Australia, France, Germany, Austria, Italy, Ukraine
-
Hospices Civils de LyonBioMérieuxCompletedVaccination | Hematopoietic Stem CellsFrance
-
Hospices Civils de LyonCompleted